Despite the controversy and known limitations of in vitro GBM cell culture, MMP9 has been proposed as a potential cancer biomarker [47], and its high expression is associated with poorer survival rates in glioma patients [48]. This evidence concerns the gene MMP9 and central nervous system cancer.